- Home
- CLPR vs ASMB Comparison
CLPR vs ASMB Comparison
Compare CLPR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- ASMB
- Stock Information
- Founded
- CLPR 2015
- ASMB 2005
- Country
- CLPR United States
- ASMB United States
- Employees
- CLPR N/A
- ASMB N/A
- Industry
- CLPR Real Estate Investment Trusts
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- ASMB Health Care
- Exchange
- CLPR Nasdaq
- ASMB Nasdaq
- Market Cap
- CLPR 72.0M
- ASMB 84.5M
- IPO Year
- CLPR 2017
- ASMB 2010
- Fundamental
- Price
- CLPR $4.41
- ASMB $10.61
- Analyst Decision
- CLPR Sell
- ASMB Buy
- Analyst Count
- CLPR 2
- ASMB 2
- Target Price
- CLPR N/A
- ASMB $35.00
- AVG Volume (30 Days)
- CLPR 71.9K
- ASMB 27.4K
- Earning Date
- CLPR 05-06-2025
- ASMB 05-07-2025
- Dividend Yield
- CLPR 8.44%
- ASMB N/A
- EPS Growth
- CLPR N/A
- ASMB N/A
- EPS
- CLPR N/A
- ASMB N/A
- Revenue
- CLPR $148,775,000.00
- ASMB $28,326,000.00
- Revenue This Year
- CLPR N/A
- ASMB $282.16
- Revenue Next Year
- CLPR N/A
- ASMB N/A
- P/E Ratio
- CLPR N/A
- ASMB N/A
- Revenue Growth
- CLPR 7.65
- ASMB N/A
- 52 Week Low
- CLPR $3.38
- ASMB $10.56
- 52 Week High
- CLPR $7.12
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- CLPR 49.90
- ASMB 30.74
- Support Level
- CLPR $4.21
- ASMB $10.56
- Resistance Level
- CLPR $4.61
- ASMB $11.41
- Average True Range (ATR)
- CLPR 0.23
- ASMB 0.75
- MACD
- CLPR -0.02
- ASMB -0.10
- Stochastic Oscillator
- CLPR 33.33
- ASMB 1.68
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.